Multiple myeloma (MM) is the second most common hematologic malignancy globally. Traditional drug therapies for MM have limited efficacy and often lead to drug resistance, and targeted drugs for MM are relatively scarce compared to other cancers. Hence, identifying new targets to overcome drug resistance and expand treatment options for MM patients is of critical importance. Our team has focused on discovering novel targets in MM, including AHA1, PNPO, and SAE1. Based on these findings, we have conducted de novo design and discovery of small molecules targeting these novel targets. Through the development of small-molecule inhibitors, we aim to elucidate the mechanisms of action of these new candidate compounds, thereby providing a foundation for their potential clinical application in the treatment of MM.

Shanliang Sun holds a Bachelor’s and Master’s degree in Medicinal Chemistry from China Pharmaceutical University, and a Doctoral degree from Vrije Universiteit Amsterdam. He is currently employed at Nanjing University of Chinese Medicine. His primary focus is on the R&D of small molecule drugs, leveraging computer-assisted techniques. His work encompasses the de novo design of small molecule drugs targeting well-established targets such as kinases and GPCRs, as well as the identification and targeting of novel, independently discovered targets.